56 completed, 11 terminated, 5 withdrawn, 2 active not recruiting. 74 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 74 | Completed 56, Terminated 11, Withdrawn 5, Active not recruiting 2 |
| Phase 1 | 11 | Completed 8, Withdrawn 2, Terminated 1 |
Follow ixabepilone: new trials by email Literature Review of ixabepilone trials Research Report on ixabepilone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. Ixabepilone Injection - Metastatic Breast Cancer | Phase 2 | Terminated | Allarity Therapeutics | 13 | 2021-03-01 | 2026-03-12 |
| Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Ixabepilone, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Yale University | 78 | 2017-04-03 | 2024-05-14 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer Ixabepilone, Capecitabine, Motesanib - Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-12-01 | 2025-05-02 | |
| Ixabepilone and SBRT For Metastatic Breast Cancer IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY - METASTATIC BREAST CANCER | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2013-08-01 | 2020-08-20 | |
| PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer Anthracycline based chemotherapy, taxane-based chemotherapy - Breast Cancer | Phase 2 | Withdrawn | Jenny C. Chang, MD | 2012-07-01 | 2023-02-02 | |
| Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Paclitaxel, Docetaxel, Abraxane - Breast Neoplasms, Breast Cancer | Phase 2 | Completed | The Methodist Hospital Research Institute | 38 | 2011-09-01 | 2023-01-23 |
| A Study of LY2523355 in Participants With Breast Cancer LY2523355, ixabepilone, pegfilgrastim - Metastatic Breast Cancer | Phase 2 | Completed | Eli Lilly and Company | 39 | 2011-08-01 | 2019-09-18 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Ixabepilone, Laboratory Biomarker Analysis - Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2010-11-01 | 2019-08-08 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Ixabepilone, Laboratory Biomarker Analysis - Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2010-09-07 | 2019-08-08 |
| Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery ixabepilone, adjuvant therapy, intensity-modulated radiation therapy - Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2010-05-26 | 2020-08-20 | |
| Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) ixabepilone, bevacizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Terminated | Providence Health & Services | 6 | 2010-02-01 | 2015-09-07 |
| Ixabepilone + Carboplatin Metastatic Breast Cancer Ixabepilone, Carboplatin - Metastatic Breast Cancer | Phase 2 | Completed | US Oncology Research | 103 | 2010-01-01 | 2016-12-07 |
| Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer Ixabepilone - Stomach Neoplasms | Phase 2 | Completed | R-Pharm | 58 | 2009-11-01 | 2020-10-28 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Bevacizumab, Carboplatin, Ixabepilone - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 349 | 2009-09-14 | 2026-09-09 |
| Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy cetuximab, carboplatin, ixabepilone - Lung Cancer | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2009-07-01 | 2012-03-06 | |
| Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer Dasatinib, Ixabepilone - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Accelerated Community Oncology Research Network | 56 | 2009-06-01 | 2014-10-13 |
| Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer Ixabepilone, Cyclophosphamide - Breast Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 168 | 2009-04-01 | 2021-11-22 |
| A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer Eribulin Mesylate, Ixabepilone - Breast Cancer | Phase 2 | Completed | Eisai Inc. | 104 | 2009-03-31 | 2023-06-22 |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy Best Practice, Ixabepilone - Bilateral Breast Carcinoma, HER2/Neu Negative | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 116 | 2009-03-30 | 2026-05-22 |
| Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer Sorafenib, Ixabepilone - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | SCRI Development Innovations, LLC | 83 | 2009-03-01 | 2014-12-22 |
Showing 20 of 74. Sign in to see all of them.
Breast Neoplasms (31) · Prostatic Neoplasms (8) · Carcinoma, Ovarian Epithelial (4) · Neoplasms (4) · Breast Neoplasms, Male (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Stomach Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2)
National Cancer Institute (NCI) (25) · R-Pharm (12) · Memorial Sloan Kettering Cancer Center (5) · SCRI Development Innovations, LLC (4) · Bristol-Myers Squibb (2) · SWOG Cancer Research Network (2) · The Methodist Hospital Research Institute (2) · University of Texas Southwestern Medical Center (2) · Accelerated Community Oncology Research Network (1) · Allarity Therapeutics (1) · Brown University (1) · Cedars-Sinai Medical Center (1) · Consorzio Oncotech (1) · Eisai Inc. (1) · Eli Lilly and Company (1)
United States (65) · Italy (7) · France (6) · Spain (5) · Germany (4) · Argentina (3) · Greece (3) · South Korea (3) · Taiwan (3) · United Kingdom (3) · Austria (2) · Japan (2) · Netherlands (2) · Poland (2) · Russia (2)
Manish A. Shah, MD (2) · Alessandro D. Santin, MD (1) · Andrea Harzstark (1) · Andres Forero-Torres, MD, CSU (1) · Angel A Rodriguez, MD (1) · Anna Pavlick (1) · Antonio T Fojo, M.D. (1) · Asal Rahimi, MD (1) · Barbara Burtness (1) · Brigitte Widemann (1) · Carol Aghajanian (1) · Carolyn McCourt (1) · Clifford A. Hudis, MD (1)
PMID 14504052, PMID 15735119, PMID 16314632, PMID 16699973, PMID 17606971, PMID 19349545, PMID 20098694, PMID 20179242, PMID 20357034, PMID 22947511, PMID 23589560, PMID 23935969, PMID 23939283, PMID 24048789, PMID 25091619, PMID 25913905, PMID 27312051, PMID 28679644, PMID 33541735, PMID 35149854, PMID 35658479, PMID 37185961, PMID 39516558
U10CA027469 (5), U10CA021115 (4), N01CM62201 (3), U10CA180868 (3), N01CM62202 (2), N01CM62206 (2), P30CA013330 (2), P30CA014599 (2), N01CM17103 (1), N01CM17104 (1), N01CM62204 (1), N01CM62209 (1), P30CA006516 (1), P30CA016086 (1), P30CA072720 (1)